AI assistant
Sending…
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2018
Dec 14, 2018
30583_dirs_2018-12-14_23ea6d06-04e0-465d-b8e6-ccef362f6763.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2018-12-12
Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-12-12 | Common Stock | M | 2000 | $17.86 | Acquired | 290290 | Direct |
| 2018-12-12 | Common Stock | S | 2000 | $93.12 | Disposed | 288290 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-12-12 | Stock Option (Right to buy Common Stock) | $17.86 | M | 2000 | Disposed | 2018-12-16 | Common Stock (2000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 182201 | Indirect |
Footnotes
F1: Trade made pursuant to a 10b5-1 plan executed on May 21, 2018.
F2: Reflects the number of options outstanding after the transactions from this specific stock option grant.
More from BIOMARIN PHARMACEUTICAL INC
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 4
Interim / Quarterly Report
2026
May 5
Report Publication Announcement
2026
May 4
M&A Activity
2026
Apr 27
M&A Activity
2026
Apr 23
Annual Report
2026
Apr 21
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 19